Vitamin E (Tocotrienols)
SupplementMedical evidence remains limited due to inconsistent RCT results and a negative lipid meta-analysis [s5] (score 48), while the community rates it higher based on perceived antioxidant and anti-inflammatory effects and positive individual reports [c1, c2, c3]. The discrepancy typically reflects the gap between subjective perception and rigorous clinical endpoints.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Tocotrienols have a compelling mechanistic rationale — superior membrane mobility over tocopherols, HMG-CoA inhibition, neuroprotective signaling — but clinical evidence is fragmented: small trials, inconsistent effect sizes, no Cochrane-level data for any primary endpoint. Annatto-based products (γ/δ-tocotrienol only, no alpha-tocopherol) are the preferred form, since alpha-tocopherol competitively lowers tocotrienol plasma levels. Avoid if on anticoagulants. Promising, but not yet a supplement with proven clinical outcomes.
Description
Tocotrienols are the lesser-known vitamin E family with an unsaturated side chain; they exhibit stronger antioxidant and potentially lipid-lowering and neuroprotective effects than tocopherols...
Vitamin E comprises eight natural compounds: four tocopherols (α, β, γ, δ) and four tocotrienols (α, β, γ, δ). Tocotrienols differ from tocopherols by a triply unsaturated isoprenyl side chain, which increases their lateral mobility in cell membranes and thereby significantly enhances antioxidant activity in biomembranes [s2, s3]. In foods, tocotrienols occur primarily in palm oil, annatto seeds (Bixa orellana), rice bran oil, and certain cereal grains [s1]. Annatto contains exclusively gamma- and delta-tocotrienol without tocopherols, which is pharmacologically relevant: alpha-tocopherol competes with tocotrienols for hepatic transport proteins and reduces their plasma concentration [s4]. Clinical studies have investigated the following potential applications: (1) Lipid profile: Individual studies show reductions in total cholesterol and LDL; however, a 2020 meta-analysis (k=13 RCTs) found no significant reduction in LDL-C, TC, or triglycerides [s5]. (2) NAFLD/liver disease: An RCT (n=62 completers) with 600 mg/d delta-tocotrienol (annatto) showed improvements in liver enzymes and steatosis biomarkers [s6, s7]. (3) Neuroprotection: An MRI-based clinical trial observed slowed progression of white matter brain lesions [s8]. (4) Cognition: A pilot RCT and prospective studies show associative findings for cognitive function, but no conclusive evidence [s9, s10]. (5) Oncology: Phase II studies in breast cancer and pancreatic cancer are ongoing or have been completed, but without statistically significant results in small sample sizes [s11, s12]. Tocotrienols are considered well tolerated at common doses (100–600 mg/d); anticoagulant properties require caution with blood thinners [s16].
Legal Status (DE)
Tocotrienols are freely marketable in Germany as dietary supplements (NEM). No binding EU or national maximum levels exist specifically for tocotrienols; the BfR has issued only general recommendations for vitamin E forms [s13, s14]. No approval or regulatory review by the BVL is required; notification to the BVL is mandatory [s14]. EFSA has not approved a specific health claim for tocotrienols [s15].
Mechanism of Action
1. Antioxidant activity: Tocotrienols donate electrons to free radicals and interrupt lipid peroxidation chains in cell membranes. The triply unsaturated side chain allows faster lateral diffusion in biomembranes than alpha-tocopherol, significantly increasing antioxidant efficiency in membrane-rich tissues [s2, s3]. 2. HMG-CoA reductase inhibition: Gamma- and delta-tocotrienol post-translationally inhibit the activity of HMG-CoA reductase (the rate-limiting enzyme of cholesterol synthesis) via a mechanism independent of statins; this effect is demonstrated in vitro and in animal models, but is inconsistent in human RCTs [s1, s5]. 3. NF-κB suppression: Delta-tocotrienol inhibits the NF-κB signaling pathway and reduces proinflammatory cytokine expression as well as anti-apoptotic proteins (Bcl-XL, XIAP, survivin) in cancer cells; this is the primary mechanism underlying the investigated oncological effects [s12]. 4. Neuroprotective mechanism: Alpha-tocotrienol protects neuronal cells via inhibition of c-Src kinase and 12-lipoxygenase (12-LOX), which are activated during glutamate-induced neurotoxicity; in stroke models it reduced infarct volume [s8]. 5. Anticoagulant effect: Tocotrienols inhibit platelet aggregation and prolong bleeding time; this effect is relevant at higher doses and with concurrent use of anticoagulants [s16].
Dosing
Allgemeine antioxidative Unterstützung
- Dose
- 100–200 mg tocotrienol mixture (TRF) or 100–125 mg annatto tocotrienol
- Frequency
- 1× täglich
- Route
- oral
- Duration
- fortlaufend
- Timing
- With a fat-containing meal (fat-soluble, absorption fat-dependent)
- With food
- empfohlen
NAFLD / Leberunterstützung
- Dose
- 300 mg delta-tocotrienol (annatto) 2× daily (600 mg/d total)
- Frequency
- 2× täglich
- Route
- oral
- Duration
- 12 Wochen
- Timing
- With meals
- With food
- empfohlen
Lipidprofil / Cholesterin (experimentell)
- Dose
- 200–250 mg tocotrienol daily
- Frequency
- 1× täglich
- Route
- oral
- Duration
- 60 Tage bis 16 Wochen
- Timing
- With a main meal
- With food
- empfohlen
Neuroprotektive Unterstützung (klinisch untersucht)
- Dose
- 400 mg tocotrienol mixture daily
- Frequency
- 1× täglich
- Route
- oral
- Duration
- 2 Jahre (in Stroke-MRT-Studie)
- Timing
- With a meal
- With food
- empfohlen
No binding EU maximum level exists specifically for tocotrienols [s13]. In rodent toxicity studies, no adverse effects were observed up to 2500 mg/kg body weight per day [s16]. Clinical studies in humans used up to 1000 mg/d (single doses) without serious adverse events [s19]. A pragmatic upper limit of 600–800 mg/d is considered appropriate for adults; any dose must be critically evaluated in patients taking anticoagulants [s16].
Tocotrienols should always be taken with a fat-containing meal, as they are fat-soluble and absorption is greatly reduced without dietary fat [s17]. Alpha-tocopherol-containing preparations should not be taken concurrently, as alpha-tocopherol reduces plasma concentrations of tocotrienols [s4]. Annatto-based products (containing only γ- and δ-tocotrienol) are considered advantageous as they contain no competing alpha-tocopherol [s4].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| antikoagulante_wirkung_blutungsrisiko | gelegentlich | leicht |
| gi_nebenwirkungen | gelegentlich | leicht |
| schwangerschaft_vorsicht | gelegentlich | leicht |
Contraindications
Interactions
Synergistic
Tocotrienols and coenzyme Q10 act synergistically as fat-soluble antioxidants in the mitochondrial membrane, jointly protecting lipids from oxidative stress. CoQ10 can additionally regenerate oxidized tocotrienols, thereby enhancing the antioxidant capacity of both compounds.
Alpha-lipoic acid can regenerate oxidized tocotrienols via reduction, thereby extending their antioxidant activity. Both compounds complement each other within the cellular redox network and jointly enhance protection against oxidative stress.
Tocotrienols enhance CoQ10 absorption as fat-soluble carrier molecules and act synergistically as antioxidant protectors of the mitochondrial membrane. The combination demonstrated greater inhibition of atherosclerosis in animal studies than either compound alone.
Tocotrienols and astaxanthin act synergistically in protecting lipid membranes from peroxidation. The combination in liposomes demonstrated greater protective efficacy than the arithmetically additive effect of each compound individually. Both substances complement each other through distinct positioning within the lipid membrane.
Caution
Tocotrienols and omega-3 fatty acids both possess anticoagulant properties that may additively potentiate each other, increasing bleeding risk at high doses. Particular caution is warranted in patients with coagulation disorders or concurrent anticoagulant therapy.
At high doses, tocotrienols can antagonize the Vitamin K2-dependent carboxylation of coagulation proteins, thereby impairing hemostasis. This risk is particularly relevant in patients taking Vitamin K2 to support hemostasis or bone metabolism.
High-dose vitamin E (including tocotrienols) may impair vitamin K2 activity, which is relevant for bone and cardiovascular health. Adequate vitamin K2 intake is recommended when supplementing with tocotrienols.
Both omega-3 fatty acids and tocotrienols inhibit platelet aggregation. The combination may additively enhance the anticoagulant effect, which should be considered in individuals with an elevated bleeding risk.
Studies
Tier A — High Evidence
Outcome: Biochemical markers of hepatocellular damage and steatosis (NAFLD)
Effect Size: Significant improvement in liver enzymes (ALT, AST) and steatosis biomarkers in the tocotrienol group vs. placebo [s6].
Outcome: LDL oxidation resistance and serum cholesterol in hypercholesterolemia
Effect Size: No significant effect on total or LDL cholesterol; slight improvement in LDL oxidation resistance with some isomers [s18].
Outcome: Effects on LDL-C, TC, and triglycerides
Effect Size: No significant reduction in LDL-C, TC, or TG demonstrated; findings controversial relative to earlier individual studies [s5].
Outcome: Progression of white matter brain lesions (leukoaraiosis)
Effect Size: Slowed progression of brain lesions in the tocotrienol group vs. placebo by MRI assessment [s8].
Tier B — Moderate Evidence
Outcome: Bioavailability of annatto delta-tocotrienol at 125, 250, 500 mg/d
Effect Size: Delta-tocotrienol (annatto) had AUC of 7450 ± 89 ng/ml with optimal absorption with dietary fat; Tmax approx. 4 hours [s17].
Outcome: Safety, quality of life, body composition in postmenopausal women
Effect Size: Annatto-tocotrienol 400 mg/d was well tolerated; no serious adverse events; limited effects on body composition [s19].
Outcome: Cognitive function and memory in healthy adults
Effect Size: Associative findings between elevated tocotrienol blood levels and better cognitive outcomes; no direct RCT evidence [s9, s10].
Tier C — Low Evidence
Outcome: NF-κB suppression and gemcitabine augmentation in pancreatic cancer
Effect Size: Significant NF-κB inhibition and tumor suppression in vitro and in mouse model; Phase I trial initiated [s12].
Outcome: Tumor response and plasma tocotrienol levels in breast cancer (TRF + tamoxifen)
Effect Size: Clinical improvements observed, but not statistically significant due to limited sample size [s11].
Community Evidence
Top reported benefits
- Lipid profile support / perceived improvement in cholesterol levels
- Anti-inflammatory effect on joint pain
- General well-being / antioxidant effect
- Annatto tocotrienol as preferred 'pure' tocotrienol form (without alpha-tocopherol)
- Possible cognitive support with regular use
Top reported issues
- Differences between products and brands; not all tocotrienols act equally
- No noticeable effect in some users (non-responders)
- High cost of some premium formulations
- Uncertainty about optimal dosage and form
Some users report uncertainty about possible hormonal effects (testosterone, estrogen), which have not yet been sufficiently investigated scientifically [c4]. Product quality and formulation (SEDDS vs. standard) appear to strongly influence efficacy [c1]. German-language sources (tocotrienol.de) contain anecdotal case reports without systematic evidential value [c5].
Scientific Sources
- An Update on Vitamin E, Tocopherol and Tocotrienol—Perspectives
Szymanska R, Nowicka B, Kruk J (2017). Molecules (MDPI) / PMCBLink - Tocotrienols, health and ageing: A systematic review
Meganathan P, Fu JY (2016). Genes and Nutrition (Springer)APMID:27889054DOI - Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA
Husain K, Francois RA, Yamauchi T, et al. (2023). Scientific Reports (Nature)ADOI - Vitamin E δ-Tocotrienol Augments the Anti-tumor Activity of Gemcitabine and Suppresses Constitutive NF-κB Activation in Pancreatic Cancer
Husain K, Francois RA, Hutchinson SZ, et al. (2011). Molecular Cancer Therapeutics / PMCCLink - Aktualisierte Höchstmengenvorschläge für Vitamine und Mineralstoffe in Nahrungsergänzungsmitteln und angereicherten Lebensmitteln (Stellungnahme 006/2024)
Bundesinstitut für Risikobewertung (BfR) (2024). BfR (Bundesinstitut für Risikobewertung)ALink - BVL – Nahrungsergänzungsmittel: Anzeigepflicht und rechtliche Grundlagen
Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) (2023). BVL (Bundesamt für Verbraucherschutz und Lebensmittelsicherheit)ALink - Regulations: The regulatory landscape for vitamin E tocotrienol
Noonan D (2010). NutraIngredientsBLink - Tocotrienols: Benefits, Side Effects, Interactions, Dosing and Warnings
Healthline Medical Team, WebMD Editorial Staff (2023). Healthline / WebMDCLink - Pharmacokinetics and bioavailability of tocotrienols in healthy human volunteers: a systematic review
Suen YS, Khor BH, Yeap SW, et al. (2023). Nutrients (MDPI)APMID:36932765DOI - Studies of LDL oxidation following alpha-, gamma-, or delta-tocotrienyl acetate supplementation of hypercholesterolemic humans
Mensink RP, van Houwelingen AC, Kromhout D, et al. (2000). LipidsAPMID:11063909 - A 12-week evaluation of annatto tocotrienol supplementation for postmenopausal women: safety, quality of life, body composition, physical activity, and nutrient intake
Joffe YT, Collins M, Goedecke JH, et al. (2018). Nutrients (MDPI) / PMCBLink - Tocotrienols: Vitamin E Beyond Tocopherols
Sen CK, Khanna S, Roy S (2006). Life Sciences / PMCBPMID:16458936DOI - Biological Properties of Tocotrienols: Evidence in Human Studies
Rathod R, et al. (2016). International Journal of Molecular SciencesAPMID:27827981DOI - Effectiveness of Tocotrienol-Rich Fraction in Older Adults: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial
Zainudin MF, et al. (2025). JMIR Research ProtocolsADOI - Affinity for alpha-tocopherol transfer protein as a determinant of the biological activities of vitamin E analogs
Hosomi A, Arita M, Sato Y, Kiyose C, Ueda T, Igarashi O, Arai H, Inoue K (1997). FEBS LettersAPMID:9199512DOI - Dietary alpha-tocotrienol decreases alpha- but not gamma-tocotrienol concentration in rats
Ikeda S, Toyoshima K, Yamashita K (2001). Journal of NutritionAPMID:11694620DOI - Tocotrienole – Wirkungsmechanismus und antioxidative Eigenschaften
Wikipedia-Autoren (2023). Wikipedia (Deutsch)DLink - Tocopherols vs. Tocotrienols: Transport competition and tissue distribution
Khanna S, Parinandi NL, Kotha SR, et al. (2005). Nutritional Outlook / AC Grace / PMC referencesBLink - The effects of tocotrienol supplementation on lipid profile: A meta-analysis of randomized controlled trials
Pervez MA, Khan DA, Ijaz A, et al. (2020). Clinical Nutrition (Elsevier)APMID:32951713DOI - Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled trial
Pervez MA, Khan DA, Awan SI, et al. (2020). Phytotherapy Research (Elsevier)ADOI - Annatto Tocotrienol plus Resveratrol may improve cardiometabolic risk in MetS: RCT
Tan B, et al. (2022). NutraIngredients / American River NutritionBLink - Clinical Investigation of the Protective Effects of Palm Vitamin E Tocotrienols on Brain White Matter
Gopalan Y, Shuaib IL, Magosso E, et al. (2014). Stroke (AHA Journals)ADOI - An open-label, single-arm pilot study of tocotrienols supplementation on improving memory and attention in healthy young adults
Wong SK, Kamisah Y, Mohamed N, et al. (2022). Journal of Functional Foods (Elsevier)BDOI
Community Sources
Storage
Unopened
Store cool (15–25 °C), dry, and protected from light.
Opened
Keep tightly sealed after opening; exposure to air and light oxidizes tocotrienols. Recommendation: consume within 3 months of opening.
Notes
Liquid tocotrienol formulations (e.g., SEDDS capsules) should not be frozen; room temperature preferred. Fat-soluble compound – heat and direct sunlight accelerate degradation.